Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2003
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220362 Novel inhibitors of formation of advanced glycation endproducts (AGEs)
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220358 A1 adenosine receptro antagonists
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220349 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220342 Use of such compounds as corticotropin releasing factor receptor antagonists in the treatment of various neurological disorders
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220324 Substituted piperazines and methods of use
11/27/2003US20030220321 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220316 Such as N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methyl phenyl)methyl)-4-methoxyphenylacetamide for stimulation of serotonin receptors
11/27/2003US20030220307 Remedial agent for osteoporosis
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220248 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
11/27/2003US20030220243 A 37 amino acid peptide that is secreted by the L-cells of the intestine in response to food ingestion, because of their ability to stimulate insulin secretion, can be used for the treatment of diabetes, obesity and releated conditions
11/27/2003US20030220229 Modulate an immunological response by T cells of Type I diabetics which can be used as an indicator; derived from a region of proinsulin that spans the junction between the B chain and C peptide; inhibiting the development/progression
11/27/2003US20030219887 Crystals of glucokinase and methods of growing them
11/27/2003US20030219880 Method for preparing (2s,3r,4s)-4-hydroxyisoleucine and analogues thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219514 Casing of a gelatin-free, water- based, set hydrocolloid gel that forms an enclosure, and at least one solid, liquid, soft or particulate center enclosed by the casing
11/27/2003US20030219485 A core containing a mixture of glipizide, a hydrophilic polymer and other excipients, a semipermeable wall surrounding the core(impermeable to content of core permeable to fluids) and a release passageways through the wall
11/27/2003US20030219481 A controlled release dosage form for oral administration containing aglipizide or salt, a controlled release matrix cotaining gelling agent, an ionizable gel strength enhcancer and an inert diluent
11/27/2003US20030219478 The filling of a pullulan based capsule including an aldehyde group in the molecule, or a precursor
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219418 Diabetic treatment by regenerating pancreas cells, genetic engineered animal embryonic pancreatic cells from different species, inserting embryonic cells into the kidney capsule of non-obese diabetic/ severe combined immunodeficiency animal
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486313A1 Composition for treating or preventing hyperuricemia
11/27/2003CA2486147A1 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486000A1 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2484646A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003CA2484233A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003CA2483770A1 Trimegestone and estrogens for treating post menopausal disorders
11/27/2003CA2483619A1 Novel compounds and their use
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482746A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/26/2003EP1364967A2 Glucagon-like insulinotropic peptides, compositions and methods
11/26/2003EP1364958A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364957A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364954A1 Dicarba-closo-dodecarborane derivatives
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364950A1 Pyridopyrimidine or naphthyridine derivative
11/26/2003EP1364647A1 Hypoglycemic agent
11/26/2003EP1364646A1 Fenofibrate-containing composition
11/26/2003EP1364069A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
11/26/2003EP1364029A1 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
11/26/2003EP1364023A2 Method of diagnosing and treating cartilage disorders
11/26/2003EP1364014A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/26/2003EP1363937A2 Immunomodulating agents from parasitic worms and method for isolation thereof
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363910A2 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
11/26/2003EP1363906A2 Heterocyclic inhibitors of erk2 and uses thereof
11/26/2003EP1363902A1 Chemical compounds
11/26/2003EP1363898A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363897A2 Antagonists of mcp-1 function and methods of use thereof
11/26/2003EP1363890A2 Melanocortin-4 receptor binding compounds and methods of use thereof
11/26/2003EP1363879A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
11/26/2003EP1363876A1 Glucocorticoid receptor modulators
11/26/2003EP1363702A1 Methods of inhibiting kinases
11/26/2003EP1363668A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/26/2003EP1363657A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/26/2003EP1363648A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
11/26/2003EP1363644A2 Modulation of gsk-3beta activity and its different uses
11/26/2003EP1363636A1 A method for the treatment of heart failure
11/26/2003EP1363632A1 Receptor selective cannabimimetic aminoalkylindoles
11/26/2003EP1363631A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363629A1 Kappa opioid receptor ligands
11/26/2003EP1363621A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
11/26/2003EP1363615A1 Preservation of body protein
11/26/2003EP1363581A2 Pyrrolo(2,3-d)pyrimidine nucleoside analogs
11/26/2003EP1363516A1 An improved process for preparing simvastatin
11/26/2003EP1363508A1 Emulsions and aqueous dispersions of phytosterols
11/26/2003EP1268487B1 Tricyclic protein kinase inhibitors
11/26/2003EP1259523B1 Pluraflavins and derivatives thereof, process for their preparation and use thereof
11/26/2003EP1204659B1 Serotonergic benzofurans
11/26/2003EP1025096B1 Substituted chroman derivatives
11/26/2003EP1025095B1 Substituted chroman derivatives
11/26/2003EP0912601B1 Suppression of immune response via inhibition of cathepsin s
11/26/2003CN1458935A Integrain binding motif containing peptides and methods of treating skeletal diseases
1 ... 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 ... 1298